Skip to Main Content

INFORMATION FOR

Gary Altwerger, MD

Assistant Professor of Obstetrics and Gynecology; Wellness committee, Obstetrics, Gynecology & Reproductive Sciences

Contact Information

Gary Altwerger, MD

Office Location

Mailing Address

  • Obstetrics, Gynecology & Reproductive Sciences

    PO Box 208063

    New Haven, CT 06520

    United States

Research Summary

Interest in understanding carboplatin hypersensitivity risk factors, elucidating its cause and determining desensitization efficacy for hypersensitive patients.

Interest in identifying and using novel targets like folic acid receptor for the treatment of biologically aggressive uterine cancer.

Use of medical cannabis for pain and peripheral neuropathy in patients with gynecologic cancer.

Coauthors

Research Interests

Drug Hypersensitivity; DNA Mismatch Repair; Lynch Syndrome II; Hereditary Breast and Ovarian Cancer Syndrome

Selected Publications

Clinical Trials

ConditionsStudy Title
Corpus Uteri; OvaryA Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination With Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
Corpus UteriA Phase II Study of Abemaciclib in Combination With Letrozole in Advanced, Recurrent or Metastatic Endometroid Endometrial Cancer
Corpus UteriA Phase II Evaluation of the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Persistent or Recurrent Endometrial Cancer
Other Female Genital; OvaryA Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
Corpus UteriA Phase II Evaluation of Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2-SN-38 Antibody-drug Conjugate, in Patients With Persistent or Recurrent Endometrial Carcinoma
Corpus Uteri; Other Female GenitalA Phase II Evaluation of Afatinib
CervixA Phase II Evaluation of Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2-SN-38 Antibody-drug Conjugate in Patients With Recurrent or Persistent Cervical Cancer
OvaryA Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-Oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]
Corpus UteriA Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined With Either Trastuzumab and Hyaluronidase-Oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma